Back

Monjas, L.; Arce, M. P.; León, R.; Egea, J.; Pérez, C.; Villarroya, M.; López, M. G.; Gil, C.; Conde, S.; Rodríguez-Franco, M. I.  [2017]. Enzymatic and solid-phase synthesis of new donepezil-based L- and D-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. Eur. J. Med. Chem. 2017, 130, 60-72.

Mansilla, A.; Chavez-Sanjuán, A.; Campillo, N. E.; Semelidou, O.; Martínez-González, L.; Infantes, L.; Gil, C.; Conde, S.; Skoulakis, E. M. C.; Ferrús, A.; Martinez, A.; Sánchez-Barrena, M. J.  [2017]. Phenothiazines regulate synaptic function by interfering the NCS-1/Ric8a complex: a novel approach for Fragile X Syndrome. PNAS 2017, 114, E999-E1008.

Medina-Rodríguez, E. M.; Bribián, A.; Boyd, A.; Palomo, V.; Pastor, J.; Lagares, A.; Gil, C.; Martínez, A.; Williams, A.; de Castro, F.  [2017]. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci. Rep. 2017, 7, 43545.

Martinez, A.; Palomo, V.; Perez, D.I.; Gil, C.  [2017]. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis. Exp. Opin. Inv. Drugs 2017, 26, 403-414

Marchena, M.; Villarejo-Zori, B.; Zaldivar-Diez, J.; Palomo, V.; Gil, C.; Hernandez-Sanchez, C.; Martinez, A.; de la Rosa, E.J.  [2017]. Small molecules targeting Glycogen Synthase Kinase 3 as potential drug candidates for the treatment of retinitis pigmentosa. J. Enz. Inh. Med. Chem. 2017, 32, 522-526.

Ponzoni, I.; Sebastian, V.; Requena, C., Roca, C.; Martínez, M. J. ; F. Cravero, F.; Díaz, M. F.; Páez, J. A.; Gomez-Arrayas, R.; Adrio, J.; Campillo, N. E.  [2017]. Hybridizing feature selection and featurelLearning approaches in QSAR modeling for drug discovery. Sci. Rep. 2017, 7, 2403.

Martín-Álvarez, R.; Paúl-Fernández, N.; Palomo, V.; Gil, C.; Martinez, A.; Mengod, G.  [2017]. A preliminary investigation of phoshodiesterase 7 inhibitor VP3.15 as therapeutic agent for the treatment of experimental autoimmune encephalomyelitis mice. J. Chem. Neuroanat. 2017, 80, 27-36

Pérez-Domper, P.; Palomo, V.; Gradari, S.; Gil, C.; de Ceballos, M. L.; Martínez, A.; Trejo, J. L.  [2017]. The GSK-3-inhibitor VP2.51 produces antidepressant effects associated with adult hippocampal neurogenesis. Neuropharmacology 2017, 116, 174-187.

Barbado, M. V.; Medrano, M.; Caballero-Velazquez, T.; Alvarez-Laderas, I.; Sanchez-Abarca, L. I.; Garcia-Guerrero, E.; Martin-Sanchez, J.; Rosado, I. V.; Piruat, J. I.; Gonzalez-Naranjo, P.; Campillo, N. E.; Paez, J. A.; Perez-Simon, J. A.  [2017]. Cannabinoid derivatives exert a potent anti-myeloma activity both in vitro and in vivo. Int. J. Cancer 2017, 140, 674-685.

Huang, S.; Wang, H.T.; Abussaud, A.; Turlova, E.; Ji, P.; Martinez, A.; Sun, H.S.; Feng, Z.P.  [2017]. GSK-3β inhibitor TDZD-8 reduces neonatal hypoxic-ischemic brain injury in mice. CNS Neurosci. & Therapeutics, 2017, 23, 405-415.

Pardo, M.; Cheng, Y.; Velmeshev, D.; Magistri, M.; Eldar-Finkelman, H.; Martinez, A.; Faghihi, M.; Jope, R.S.; Beurel, E.  [2017]. Intranasal siRNA administration can regulate learning and ameliorate deficits in Fragile X syndrome mice. J Clinical Investigation Insight, 2017, 2(6):e91782.

Chierrito, T.; Pedersoli-Mantoani, S.; Roca, C.; Requena, C.; Sebastian-Perez, V.; Castillo, W.; Moreira, N.; Perez, C.; Sakamoto, E.; Takashashi, C.; Jimenez-Barbero, J.; Cañada, F.J.; Campillo, N.E.; Martinez, A.; Carvalho, I.  [2017]. From dual binding site acetylcholinesterase inhibitors to allosteric modulators: A new avenue for disease-modifying drugs in Alzheimer’s disease. Eur. J. Med. Chem. 2017, 39, 773-791

Palomo, V.; Martinez, A.  [2017]. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin. Ther. Pat. 2017, 27, 657-666.

Morales-García, J. A.; Echeverry-Alzate, V.; Alonso-Gil, S.; Sanz-SanCristobal, M.; Lopez-Moreno, J. A.; Gil, C.; Martinez, A.; Santos, A.; Perez-Castillo, A.  [2017].  Phosphodiesterase7 inhibition activates adult neurogenesis in the hippocampus and subventricular zone in vitro and in vivo. Stem Cells, 2017, 35, 458-472.

Wang, H.; Huang, S.; Yan, K.; Fang, X.; Abussaud, A.; Martinez, A.; Sun, H. S.; Feng, Z. P.  [2016]. Tideglusib, a chemical inhibitor of GSK3β, attenuates hypoxic-ischemic brain injury in neonatal mice. Biochim. Biophys. Acta. 2016, 1860, 2076-2085

Lipina, T.; Jekielek, M.; Beregovoy, N. A.; Starostina, M. V.; Palomo, V.; Perez, D. I.; Martinez, A.; Roder, J. C.  [2016]. Inhibition of glycogen synthase kinase 3 prevents synaptic long-term depression and facilitates cognition in C57bl/6J mice. OM&P 2016, 2, 87-102.

Silva, T.; Mohamed, T.; Shakeri, A.; Rao, P. P.; Martínez-González, L.; Pérez, D. I.; Martínez, A.; Valente, M. J.; Garrido, J.; Uriarte, E.; Serrão, P.; Soares-da-Silva, P.; Remião, F.; Borges, F  [2016]. Development of blood-brain barrier permeable nitrocatechol-based catechol O-methyltransferase inhibitors with reduced potential for hepatotoxicity. J. Med. Chem. 2016, 59, 7584-7597

Martinez, A.; Gil, C.  [2016]. Heterocycles containing nitrogen and sulphur as potent biologically active scaffolds. Privileged Scaffolds in Medicinal Chemistry. Ed. S. Bräse, Royal Society of Chemistry. 231-262.

Sebastian, V.; Manoli, M.-T.; Pérez, D. I.; Gil, C.; Mellado, E.; Martinez, A.; Espeso, E.; Campillo, N. E.  [2016]. New applications for known drugs: Human Glycogen Synthase Kinase 3 inhibitors as modulators of Aspergillus fumigatus growth. Eur. J. Med. Chem. 116, 281-289.

Martín-Requero, A.; Alquézar, C.; Salado, I. G.; de la Encarnación, A.; Pérez, D. I.; Moreno, F.; Gil, C.; López de Munain, A.; Martínez, A.  [2016]. Targeting TDP-43 phosphorylation by Casein Kinase-1δ inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol. Neurodegener. 11:36.